Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/9993
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Identifiers
ISSN: 1758-8340
eISSN: 1758-8359
WOS ID: 000478583000001
Scopus EID: 2-s2.0-85066835008
PMID: 31205497
Embase PUI: L627801054
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Bellet, Meritxell; Ahmad, Faten; Villanueva, Rafael; Valdivia, Carolina; Palomino-Doza, Julian; Ruiz, Ada; Gonzalez, Xavier; Adrover, Encarna; Azaro, Analia; Valls-Margarit, Maria; Lluis Parra, Josep; Aguilar, Juan; Vidal, Maria; Martin, Anastasi; Gavila, Joaquin; Escriva-de-Romani, Santiago; Perello Martorell, Antonia
Publication date
2019-05Document type
review articleCitation
Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019 May;11:1-43.Abstract
Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
Publisher version
https://dx.doi.org/10.1177/1758835919833867Keywords
CDK inhibitorspalbociclib
ribociclib
breast cancer
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica